Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an open-label, phase 1/2 study-Reference-Cited by-同舟云学术

Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an open-label, phase 1/2 study

Published:2021-09 Issue:10306 Volume:398 Page:1157-1169
ISSN:0140-6736
Container-title:The Lancet
language:en
Short-container-title:The Lancet

Author:

Hutchings Martin,Mous Rogier,Clausen Michael Roost,Johnson Peter,Linton Kim M,Chamuleau Martine E D,Lewis David John,Sureda Balari Anna,Cunningham David,Oliveri Roberto S,Elliott Brian,DeMarco Dena,Azaryan Ada,Chiu Christopher,Li Tommy,Chen Kuo-mei,Ahmadi Tahamtan,Lugtenburg Pieternella J

Publisher

Elsevier BV

Subject

General Medicine

Reference30 articles.

1. Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study;Crump;Blood,2017

2. Rituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma;Kewalramani;Blood,2004

3. R-ESHAP as salvage therapy for patients with relapsed or refractory diffuse large B-cell lymphoma: the influence of prior exposure to rituximab on outcome. A GEL/TAMO study;Martín;Haematologica,2008

4. Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era;Gisselbrecht;J Clin Oncol,2010

5. Ofatumumab versus rituximab salvage chemoimmunotherapy in relapsed or refractory diffuse large B-cell lymphoma: the ORCHARRD study;van Imhoff;J Clin Oncol,2017

Cited by 207 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The rules of T-cell engagement: current state of CAR T cells and bispecific antibodies in B-cell lymphomas;Blood Advances;2024-09-10

2. Progresses of T-cell-engaging bispecific antibodies in treatment of solid tumors;International Immunopharmacology;2024-09

3. Current and future therapies for follicular lymphoma;Experimental Hematology & Oncology;2024-08-22

4. Pathological landscape of tumor flare reaction to epcoritamab treatment;International Journal of Hematology;2024-08-12

5. Targeting the tumor microenvironment for treating double-refractory chronic lymphocytic leukemia;Blood;2024-08-08